Table 1.
Commercially available PRP systems and their PRP preparations
| System | Company | Blood volume required (mL) | Concentrated volume produced (mL) | Processing time (min) | PPP produced? | Increase in [platelets] (times baseline) | Platelet capture efficiency (% yield) |
|---|---|---|---|---|---|---|---|
| Leukocyte-rich PRP | |||||||
| Angel | Arthrex | 52 [6] | 1–20a | 17 [6] | + | 10a | 56–75% [6] |
| GenesisCS | EmCyte | 54 [6] | 6 [6] | 10 [6] | + | 4–7 [6] | 61 ± 12% [6] |
| GPS III | Biomet | 54 [6] | 6 [6] | 15 [6] | + | 3–10 [6] | 70 ± 30% [6] |
| Magellan | Isto Biologics/Arteriocyte | 52 [6] | 3.5–7 [6] | 17 [6] | + | 3–15 [6] | 86 ± 41% [6] |
| SmartPReP 2 | Harvest | 54 [6] | 7 [6] | 14 [6] | + | 5–9 [6] | 94 ± 12% [6] |
| Leukocyte-poor PRP | |||||||
| Autologous conditioned plasma (ACP) | Arthrex | 11 [7] | 4 [7] | 5 [7] | – | 1.3 [7] | 48 ± 7% [7] |
| Cascade | MTF | 18 [8] | 7.5 [8] | 6 [8] | – | 1.6 [8] | 68 ± 4% [8] |
| Clear PRP | Harvest | 54a | 6.5a | 18a | + | 3–6a | 62 ± 5%a |
| Pure PRP | EmCyte | 50a | 6.5a | 8.5a | + | 4–7a | 76 ± 4%a |
aData obtained from manufacturers’ promotional literature or internal studies